Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures

British Journal of Pharmacology

Volumn 146, Issue 3, 2005, Pages 324-332

  Wang, Guosu ^a   Franklin, Richard ^b   Hong, Ying ^a   Erusalimsky, Jorge D ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Shire Pharmaceuticals   (United Kingdom)

Author keywords

Anagrelide; Haematopoiesis; Megakaryocyte; Metabolites; Myeloproliferative disorders; Phosphodiesterase

Indexed keywords

2 AMINO 5,6 DICHLORO 3,4 DIHYDROQUINAZOLINE; 6,7 DICHLORO 3 HYDROXY 1,5 DIHYDROIMIDAZO[2,1 B]QUINAZOLIN 2 ONE; ANAGRELIDE; BCH 24426; CD34 ANTIGEN; DRUG METABOLITE; ERYTHROPOIETIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; QUINAZOLINE DERIVATIVE; RL 603; STROMAL CELL DERIVED FACTOR 1ALPHA; THROMBOPOIETIN; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CELL LINEAGE; CELL MATURATION; CELL MIGRATION; CELL STIMULATION; CELL TYPE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; ERYTHROID CELL; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IC 50; MEGAKARYOCYTE; MEGAKARYOPOIESIS; PRIORITY JOURNAL; STEM CELL;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANTIGENS, CD34; CELL DIFFERENTIATION; CELL MOVEMENT; CELLS, CULTURED; FIBRINOLYTIC AGENTS; HEMATOPOIETIC STEM CELLS; HUMANS; IMIDAZOLES; MEGAKARYOCYTES; PLATELET AGGREGATION INHIBITORS; QUINAZOLINES;

EID: 27144481413     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706341     Document Type: Article

References (23)

1. ABE, A.W., NOVECK, R.J. & FLEMING, J.S. (1984). Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers. Thromb. Haemost., 52, 325-328.
2. BEAVO, J.A. (1995). Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev., 75, 725-748.
3. BOBIK, R., HONG, Y., BREIER, G., MARTIN, J.F. & ERUSALIMSKY, J.D. (1998). Thrombopoietin stimulates VEGF release from c-Mpl-expressing cell lines and haematopoietic progenitors. FEBS Lett., 423, 10-14.
4. ERUSALIMSKY, J.D., HONG, Y. & FRANKLIN, R. (2002). Is the platelet lowering activity of anagrelide mediated by its major metabolite 2-amino-5,6-dichloro-3,4-dihydroquinazoline (RL603)? Exp. Hematol., 30, 625-626.
5. FLEMING, J.S. & BUYNISKI, J.P. (1979). A potent new inhibitor of platelet aggregation and experimental thrombosis, anagrelide (BL-4162A). Thromb. Res., 15, 373-388.
6. GILLESPIE, E. (1988). Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity. Biochem. Pharmacol., 37, 2866-2868.
7. HONG, Y. & ERUSALIMSKY, J.D. (2002). Comparison of the pharmacological mechanisms involved in the platelet lowering actions of anagrelide and hydroxyurea: a review. Platelets, 13, 381-386.
8. LAM, A.C., LI, K., ZHANG, X.B., LI, C.K., FOK, T.F., CHANG, A.M., JAMES, A.E., TSANG, K.S. & YUEN, P.M. (2001). Preclinical ex vivo expansion of cord blood hematopoietic stem and progenitor cells: duration of culture; the media, serum supplements, and growth factors used; and engraftment in NOD/SCID mice. Transfusion (Paris), 41, 1567-1576.
9. LANE, W.J., HATTORI, K., DIAS, S., PEERSCHKE, E.I., MOORE, M.A., BLANSET, D.L., LANG, P.C., PETRONE, M. & RAFII, S. (2001). Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation. Exp. Hematol., 29, 1417-1424.
10. LONG, M.W. (1993). Population heterogeneity among cells of the megakaryocyte lineage. Stem Cells, 11, 33-40.
11. MATHUR, A., HONG, Y., MARTIN, J. & ERUSALIMSKY, J. (2001). Megakaryocytic differentiation is accompanied by a reduction in cell migratory potential. Br. J. Haematol., 112, 459-465.
12. MATHUR, A., HONG, Y., WANG, G. & ERUSALIMSKY, J.D. (2004). Assays of megakaryocyte development: surface antigen expression, ploidy, and size. Methods Mol. Biol., 272, 309-322.
13. MAZUR, E.M., ROSMARIN, A.G., SOHL, P.A., NEWTON, J.L. & NARENDRAN, A. (1992). Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood, 79, 1931-1937.
14. PESCATORE, S.L. & LINDLEY, C. (2000). Anagrelide: a novel agent for the treatment of myeloproliferative disorders. Expert Opin. Pharmacother., 1, 537-546.
15. RAFII, S. & LANE, W.J. (2002). Is the platelet lowering activity of anagrelide mediated by its major metabolite 2-amino-5,6-dichloro-3,4- dihydroquinazoline (RL603)? In response. Exp. Hematol., 30, 626-627.
16. RUPPERT, D. & WEITHMANN, K.U. (1982). HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro. Life Sci., 31, 2037-2043.
17. SEILER, S., ARNOLD, A.J., GROVE, R.I., FIFER, C.A., KEELY JR, S.L. & STANTON, H.C. (1987). Effects of anagrelide on platelet cAMP levels, cAMP-dependent protein kinase and thrombin-induced Ca+ + fluxes. J. Pharmacol. Exp. Ther., 243, 767-774.
18. SILVERSTEIN, M.N., PETITT, R.M., SOLBERG JR, L.A., FLEMING, J.S., KNIGHT, R.C. & SCHACTER, L.P. (1988). Anagrelide: a new drug for treating thrombocytosis. N. Engl. J. Med., 318, 1292-1294.
19. SOLBERG JR, L.A., TEFFERI, A., OLES, K.J., TARACH, J.S., PETITT, R.M., FORSTROM, L.A. & SILVERSTEIN, M.N. (1997). The effects of anagrelide on human megakaryocytopoiesis. Br. J. Haematol., 99, 174-180.
20. SUDO, T., TACHIBANA, K., TOGA, K., TOCHIZAWA, S., INOUE, Y., KIMURA, Y. & HIDAKA, H. (2000). Potent effects of novel antiplatelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem. Pharmacol., 59, 347-356.
21. TANG, K.M., JANG, E.K. & HASLAM, R.J. (1994). Photoaffinity labelling of cyclic GMP-inhibited phosphodiesterase (PDE III) in human and rat platelets and rat tissues: effects of phosphodiesterase inhibitors. Eur. J. Pharmacol., 268, 105-114.
22. TOMER, A. (2002). Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. Blood, 99, 1602-1609.
23. VAN DEN OUDENRIJN, S., VON DEM BORNE, A.E. & DE HAAS, M. (2001). Influence of medium components on ex vivo megakaryocyte expansion. J. Hematother. Stem Cell Res., 10, 193-200.